ClinicalTrials.gg
CompletedNCT00478634Updated Nov 2, 2012

A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

A Phase 1 interventional study of RAD001, Cetuximab, Irinotecan in Colorectal Cancer, Colorectal Carcinoma and Colorectal Tumors, sponsored by Novartis Pharmaceuticals. Completed at 16 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-11-02.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies testing everolimus in Colorectal Neoplasms — 2 open to participants now, 2 under way, none of them phase 3. Everolimus · Colorectal Neoplasms.

Enrollment
9th of 10
19 · median 41
Started
2007
with 1 other
Phase 1
Only one
of the 10
Registered
4th of 10
by date
Lead sponsor
2 of 10
Novartis Pharmaceuticals

Among the 10 studies testing everolimus in Colorectal Neoplasms, this one is the 9th largest by enrollment, is one of 2 that started in 2007, is the only one in phase 1, and was the 4th registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

2 of the 10 studies testing everolimus in Colorectal Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing everolimus in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This study will assess the safety of RAD001 when given together with cetuximab and irinotecan

03

Conditions studied

  • Colorectal Cancer
  • Colorectal Carcinoma
  • Colorectal Tumors
  • Neoplasms, Colorectal

Keywords

  • Colorectal Cancer
  • Colorectal Carcinoma
  • Colorectal Tumors
  • Neoplasms, Colorectal
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old and ≤ 65 years old.
  • Patients with CRC. Confirmation of CRC diagnosis by histological or cytological specimen from original resection of primary tumor.
  • Patients who progressed despite prior therapy with FOLFOX (5FU and oxaliplatin) plus bevacizumab or XELOX (capecitabine and oxaliplatin) plus bevacizumab.
  • Patients with at least one by as determined by Computer Tomography (CT) Scan, Magnetic Resonance Imaging (MRI) or physical examination.
  • Patients with a of 0 or 1.

Exclusion criteria

Exclusion criteria:

  • Patients with Gilbert's syndrome or any other syndrome associated with deficient glucoronidation of .
  • Patients who are homozygous for the UGT1A1*28 allele as determined by sequencing.
  • Patients who have received previous irinotecan-based therapy.
  • Prior treatment with an mTOR inhibitor.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    A1: RAD001 + cetuximab + irinotecan

    RAD001 30mg weekly oral, 400mg/m2, loading i.v. (250mg/m2 for subsequent weekly dose i.v.), 350mg/m2 every 3 weeks i.v.

    Drug: RAD001, Cetuximab, Irinotecan

  • Experimental
    B1 dose: RAD001 + cetuximab + irinotecan

    RAD001 30mg weekly oral, 400mg/m2 loading i.v (250mg/m2 for subsequent weekly dose i.v.), 250mg/m2 every 3 weeks i.v.

    Drug: RAD001, Cetuximab, Irinotecan

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities

    each cycle was 21 days

    Time frame: at end of cycle 2

Secondary outcomes

  1. Pharmacokinetics of RAD001, Irinotecan and SN-38

  2. Progressions Free Survival

  3. Overall Survival

  4. Objective Response Rate

07

Study locations

16 sites
  • Highlands Oncology Group
    Fayetteville, Arkansas 72701, United States
  • Comprehensive nBlood and Cancer Care
    Bakersfield, California 93309, United States
  • UCSD - Moores Cancer Center
    La Jolla, California 92037, United States
  • Comprehensive Cancer Care
    Los Angeles, California 90095, United States
  • North Valley Hematology/Oncology Medical Group: The Thomas & Dorothy Leavey Cancer Center
    Northridge, California 91325, United States
  • Cancer Care Associates Medical Group, Inc.
    Redondo Beach, California 90277, United States
  • Norwalk Hospital
    Norwalk, Connecticut 06850, United States
  • Gerogetown University Lombardi Cancer Center
    Washington, District of Columbia 20057, United States
  • H. Lee Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Oncology Specialists
    Park Ridge, Illinois 60068, United States
  • Nevada Cancer Institute
    Las Vegas, Nevada 89135, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Richmond University Medical Center
    Staten Island, New York 10310, United States
  • UNC School of Medicine
    Chapel Hill, North Carolina 27599, United States
  • Oncology/Hematology Associates
    Bethlehem, Pennsylvania 18017, United States
  • Arlington Cancer Center
    Arlington, Texas 76012, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2007
First posted
May 25, 2007
Start
May 2007
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Last update
Nov 2, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00478634
Responsible party
Sponsor
First posted
May 25, 2007
Start date
May 2007
Primary completion
Sep 2009
Completion
Sep 2009
Last update
Nov 2, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Everolimus · Cetuximab · Irinotecan

Start the discussion